The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region
Long COVID is a debilitating chronic condition that has affected over 100 million people globally
PrecisionLife to analyse OXEGENE data to improve mechanistic understanding of endometriosis and identify novel drug targets to support the development of new personalised treatments
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
Indian government seeks to promote collaboration with stakeholders and harness potential for achieving growth and development of sector
The Indian pharmaceutical industry includes a network of 3,000 drug companies and 10,500 manufacturing units. It is projected to reach a value of US$ 130 billion by 2030
The need is to focus on an enabling framework to bridge the digital divide across countries specifically amongst low-and-middle-income countries
Subscribe To Our Newsletter & Stay Updated
